Clovis Oncology Inc., of Boulder, Colo., reported 2018 U.S. sales of PARP inhibitor Rubraca (rucaparib) totaling $95.4 million, including $30.4 million for the fourth quarter. The company reported a net loss of $99.3 million, or $1.88 per share, for the fourth quarter, and a net loss of $368 million, or $7.07 per share, for the full year. As of Dec. 31, Clovis had cash, equivalents and available-for-sale securities of $520.1 million. Shares of Clovis (NASDAQ:CLVS) closed Tuesday at $26.05, up 58 cents.